Biobetters vs. Biosimilars: Opportunities, threats & strategic implications
Gregory K Bell
The evolving landscape of biobetters: Advantages & challenges of being better
Kooros Motamed-Larijani
Pharmacogenomic aspects in the treatment of type 2 diabetes
Ivan Tkac
Biobetters, regulatory frameworks and the Right to Health in Africa
Mandla S Makhanya
Eric Ka Wai Hui
Steven J Durham
Biosimilars by approval - Biogenerics in practice?
Steinar Madsen
Yite Robert Chou
Marika Kamberi
Yara Peluso Cid